180
Participants
Start Date
September 13, 2022
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2030
Adjuvant treatment for MRD positivity
The MRD positive group would receive icotinib as adjuvant treatment. When the peripheral blood MRD turned negative, the subjects entered the drug withdrawal observation period. When the MRD turned positive again, the subjects resumed icotinib treatment. If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.
NOT_YET_RECRUITING
Beijing Friendship Hospital, Capital Medical University, Beijing
NOT_YET_RECRUITING
Chongqing University Three Gorges Hospital, Chongqing
NOT_YET_RECRUITING
The First People's Hospital of Foshan, Foshan
NOT_YET_RECRUITING
Fujian Medical University Union Hospital, Fuzhou
NOT_YET_RECRUITING
Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou
NOT_YET_RECRUITING
Nanfang Hospital Southern Medical University, Guangzhou
RECRUITING
Guangdong Provincial People's Hospital, Guanzhou
NOT_YET_RECRUITING
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei
NOT_YET_RECRUITING
The Affiliated Hospital of Inner Mongolia Hospital, Hohhot
NOT_YET_RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
NOT_YET_RECRUITING
Zhongshan Hospital Fudan University, Shanghai
NOT_YET_RECRUITING
Shenzhen People's Hospital, Shenzhen
NOT_YET_RECRUITING
Tongji Hospital Tongji College of HUST, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Zhongshan City People's Hospital, Zhongshan
Guangdong Association of Clinical Trials
OTHER